^ Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS (November 2011). "Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats". Psychopharmacology. 218 (2): 443–457. doi:10.1007/s00213-011-2342-0. PMID 21667074.
At least 38 states considered legislation related to industrial hemp in 2018. These bills ranged from clarifying existing laws to establishing new licensing requirements and programs. At least six states – Alaska, Arizona, Kansas, Missouri, New Jersey and Oklahoma – enacted legislation in 2018 establishing hemp research and industrial hemp pilot programs. Georgia created the House Study Committee on Industrial Hemp Production. States, already allowing for industrial hemp programs, continued to consider policies related to licensure, funding, seed certification, and other issues. For example, Tennessee amended its Commercial Feed Law to include hemp.
Over the ages, countless innovations have attempted to improve on the basic experience of inhaling the smoke of combusted cannabis. As a result, there are numerous ways to smoke marijuana. The rolling technique is at the root of joints, blunts, and spliffs. On the other hand, glassware and other devices are essential for smoking weed out of a pipe, bong, or bubbler.
I have digenerative disc disease/4 bulgin discs was taking 9---10mg hydrocodones a day... i started with 3 drops of 300mg and within 5 mins started feeling better than i have theses last 6 years or so... not only that, the inflamation has decrease substantially, i wake up with energy and have begun to work out again... if im making it seem like a miracle drug... its because it is... so the first week i took 3 drops twice a day... now 3 weeks in... im taking about 5 drops 3 times a day and zero pain pills... for the first time in years i have taken control of my life agin... not depending on doctor scripts/bills etc....
Cannabis Ruderalis – Thought to be a cannabis species originating in central Asia, it flowers earlier, is much smaller, and can withstand much harsher climates than either Cannabis indica or Cannabis sativa. This species purportedly buds based on age rather than changes in length of daylight, known as auto-flowering. It’s used primarily for food production, such as hemp seeds and hemp seed oil.
What is cannabis?Cannabis is a drug that comes from Indian hemp plants such as Cannabis sativa and Cannabis indica. The main active chemical in cannabis is THC (delta-9 tetrahydrocannabinol).Cannabis is a depressant drug. Depressant drugs do not necessarily make you feel depressed. Rather, they slow down the activity of the central nervous system and the messages going between the brain and the body. When large doses of cannabis are taken it may also produce hallucinogenic effects.For information on synthetic cannabinoids, see our "Legal high" facts page.Other namesCannabis is also known as grass, pot, hash, weed, reefer, dope, herb, mull, buddha, ganja, joint, stick, buckets, cones, skunk, hydro, yarndi, smoke and hooch.What does cannabis look like?Leaves from the cannabis plant are bright green and have a distinctive shape with five or seven leaflets. The flowering tops and upper leaves are covered in a sticky resin.Cannabis is used for the psychoactive (mind and mood-altering) effects of THC and other active ingredients. THC is the chemical in cannabis that makes you feel “high”.There are three main forms of psychoactive cannabis: marijuana, hashish and hash oil.Marijuana is the most common and least potent form of cannabis. Marijuana is the dried leaves and flowers of the plant.Hashish (“hash”) is dried cannabis resin, usually in the form of a small block. The concentration of THC in hashish is higher than in marijuana, producing stronger effects.Hash oil is a thick, oily liquid, golden brown to black in colour, which is extracted from cannabis. Hash oil is the strongest form of cannabis.How and why is it used?The different forms of cannabis are used in different ways:Marijuana is smoked in hand-rolled cigarettes (joints), or in a pipe (a bong).Hashish is usually added to tobacco and smoked, or baked and eaten in foods such as hash cookies.Hash oil is usually spread on the tip or paper of a cigarette and then smoked.Cannabis and hash can also be smoked in a vaporiser. Vaporisers heat cannabis to temperatures that release its active ingredients while minimising the toxins associated with burning.The THC in cannabis is absorbed into the bloodstream through the walls of the lungs (if smoked), or through the walls of the stomach and intestines (if eaten). The bloodstream carries the THC to the brain, producing the “high” effects. Drugs inhaled get into the bloodstream quicker than those eaten. This means that the effects of cannabis when smoked occur more rapidly than when eaten.Paper and textilesSome species of cannabis have few psychoactive effects. These plants are used to produce hemp fibre for use in paper, textiles and clothing.Medical usesCannabis has been used for medical purposes for many centuries. It has been reported that cannabis may be useful to help conditions such as:nausea and vomiting, particularly when associated with chemotherapywasting and severe weight loss, in people with HIV/AIDS, cancer, or anorexia nervosa, as it may be used as an appetite stimulantpain relief, for example in people with cancer and arthritisrelief from symptoms of some neurological disorders that involve muscle spasms, including multiple sclerosis and spinal cord injuryglaucomaepilepsyasthma.For more information, please click on the Australian Drug Foundation's DrugInfo Clearinghouse web site link below.
The etymology is uncertain but there appears to be no common Proto-Indo-European source for the various forms of the word; the Greek term kánnabis is the oldest attested form, which may have been borrowed from an earlier Scythian or Thracian word. Then it appears to have been borrowed into Latin, and separately into Slavic and from there into Baltic, Finnish, and Germanic languages. Following Grimm's law, the "k" would have changed to "h" with the first Germanic sound shift, after which it may have been adapted into the Old English form, hænep. However, this theory assumes that hemp was not widely spread among different societies until after it was already being used as a psychoactive drug, which Adams and Mallory (1997) believe to be unlikely based on archaeological evidence. Barber (1991) however, argued that the spread of the name "kannabis" was due to its historically more recent drug use, starting from the south, around Iran, whereas non-THC varieties of hemp are older and prehistoric. Another possible source of origin is Assyrian qunnabu, which was the name for a source of oil, fiber, and medicine in the 1st millennium BC.
Among members of the public-health community, it is impossible to spend five minutes on the e-cigarette question without getting into an argument. And this is nicotine they are arguing about, a drug that has been exhaustively studied by generations of scientists. We don’t worry that e-cigarettes increase the number of fatal car accidents, diminish motivation and cognition, or impair academic achievement. The drugs through the gateway that we worry about with e-cigarettes are Marlboros, not opioids. There are no enormous scientific question marks over nicotine’s dosing and bio-availability. Yet we still proceed cautiously and carefully with nicotine, because it is a powerful drug, and when powerful drugs are consumed by lots of people in new and untested ways we have an obligation to try to figure out what will happen.
Cannabinoids may offer significant “side benefits” beyond analgesia. These include anti-emetic effects, well established with THC, but additionally demonstrated for CBD (Pertwee 2005), the ability of THC and CBD to produce apoptosis in malignant cells and inhibit cancer-induced angiogenesis (Kogan 2005; Ligresti et al 2006), as well as the neuroprotective antioxidant properties of the two substances (Hampson et al 1998), and improvements in symptomatic insomnia (Russo et al 2007).
^ Jump up to: a b Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogué S, Torrens M, Pujol J, Farré M, Martin-Santos R (2013). "Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings". PLOS One. 8 (2): e55821. Bibcode:2013PLoSO...855821B. doi:10.1371/journal.pone.0055821. PMC 3563634. PMID 23390554. The most consistently reported brain alteration was reduced hippocampal volume which was shown to persist even after several months of abstinence in one study and also to be related to the amount of cannabis use Other frequently reported morphological brain alterations related to chronic cannabis use were reported in the amygdala the cerebellum and the frontal cortex...These findings may be interpreted as reflecting neuroadaptation, perhaps indicating the recruitment of additional regions as a compensatory mechanism to maintain normal cognitive performance in response to chronic cannabis exposure, particularly within the prefrontal cortex area.
There is concern that cannabis may contribute to cardiovascular disease, but as of 2018, evidence of this relationship was unclear. Cannabis is believed to be an aggravating factor in rare cases of arteritis, a serious condition that in some cases leads to amputation. Because 97% of case-reports also smoked tobacco, a formal association with cannabis could not be made. If cannabis arteritis turns out to be a distinct clinical entity, it might be the consequence of vasoconstrictor activity observed from delta-8-THC and delta-9-THC. Other serious cardiovascular events including myocardial infarction, stroke, sudden cardiac death, and cardiomyopathy have been reported to be temporally associated with cannabis use. Research in these events is complicated because cannabis is often used in conjunction with tobacco, and drugs such as alcohol and cocaine. These putative effects can be taken in context of a wide range of cardiovascular phenomena regulated by the endocannabinoid system and an overall role of cannabis in causing decreased peripheral resistance and increased cardiac output, which potentially could pose a threat to those with cardiovascular disease. There is some evidence from case reports that cannabis use may provoke fatal cardiovascular events in young people who have not been diagnosed with cardiovascular disease. Smoking cannabis has also been shown to increase the risk of myocardial infarction by 4.8 times for the 60 minutes after consumption.
"In response to DEA actions to block seeds imported by some states in order to grow industrial hemp and to avoid future similar DEA actions to stall full implementation of the hemp provision of the farm bill, Congress acted swiftly. Both the House and Senate FY2015 Commerce-JusticeScience (CJS) appropriations bills contained provisions to block federal law enforcement authorities from interfering with state agencies and hemp growers and counter efforts to obstruct agricultural research. The enacted FY2015 appropriation blocked federal law enforcement authorities from interfering with state agencies, hemp growers, and agricultural research.46 The provision stated that 'none of the funds made available' to the U.S. Justice Department and DEA 'may be used in contravention' of the 2014 farm bill.
Cannabis terpenoids also display numerous attributes that may be germane to pain treatment (McPartland and Russo 2001). Myrcene is analgesic, and such activity, in contrast to cannabinoids, is blocked by naloxone (Rao et al 1990), suggesting an opioid-like mechanism. It also blocks inflammation via PGE-2 (Lorenzetti et al 1991). The cannabis sesquiterpenoid β-caryophyllene shows increasing promise in this regard. It is anti-inflammatory comparable to phenylbutazone via PGE-1 (Basile et al 1988), but simultaneously acts as a gastric cytoprotective (Tambe et al 1996). The analgesic attributes of β-caryophyllene are increasingly credible with the discovery that it is a selective CB2 agonist (Gertsch et al 2007), with possibly broad clinical applications. α-Pinene also inhibits PGE-1 (Gil et al 1989), while linalool displays local anesthetic effects (Re et al 2000).
Perhaps the most prevalent use for CBD is for pain management. The reality is that pain will affect everyone at some point in his or her life, and it’s comforting to know that there is a natural remedy that can help. The use of a natural remedy is especially important for those suffering from neuropathic pain and chronic pain – or pain that lasts for more than a few months. Chronic pain affects more than 3 million people in the United States every year – and the worst part? It can’t be cured. However, it can be treated and the irony is that in the United States, the most common medical treatments are nerve blocks, steroids, and narcotics (opioids) – many of which carry significant risk of side effects and addiction. Even over the counter non-steroidal anti-inflammatory drugs (NSAIDs) like Aspirin and ibuprofen are dangerous when used regularly – hospitalizing over 100,000 people each year and killing approximately 15,000. However, dangerous narcotics and NSAIDs are not your only option for pain relief! In addition to physical therapy and self-care, you can incorporate CBD into your treatment regimen for natural, plant-based pain relief. CBD is fundamentally different than most prescribed painkillers, as it’s not addictive, non-toxic, and has very minimal (if any) side effects.
^ Blest-Hopley G, Giampietro V, Bhattacharyya S (May 2018). "Residual effects of cannabis use in adolescent and adult brains - A meta-analysis of fMRI studies". Neuroscience and Biobehavioral Reviews. 88: 26–41. doi:10.1016/j.neubiorev.2018.03.008. PMID 29535069. This may reflect the multitude of cognitive tasks employed by the various studies included in these meta-analyses, all of which involved performing a task thereby requiring the participant to reorient their attention and attempt to solve the problem at hand and suggest that greater engagement of this region indicates less efficient cognitive performance in cannabis users in general, irrespective of their age.
A limited number of studies have examined the effects of cannabis smoking on the respiratory system. Chronic heavy marijuana smoking is associated with coughing, production of sputum, wheezing, and other symptoms of chronic bronchitis. The available evidence does not support a causal relationship between cannabis use and chronic obstructive pulmonary disease. Short-term use of cannabis is associated with bronchodilation. Other side effects of cannabis use include cannabinoid hyperemesis syndrome.
The ECS is responsible for setting the baseline activity levels of our immune system and nervous system, which then work to maintain our health. When the ECS falls out of whack, the systems that are regulated by it can begin to malfunction. CBD promotes the normal health and function of the endocannabinoid system, so it’s possible that CBD can help to alleviate the symptoms of conditions that are caused by dysfunction of the endocannabinoid system.
The exploding recreational market for marijuana has rapidly popularized many methods of consuming cannabis that was decidedly part of the fringe just a few short years ago. Smoking marijuana remains the most widely embraced method, due to the greater accessibility of marijuana flower. But legal recreational cannabis is introducing many marijuana users to new forms of the drug, especially concentrates and edibles. Here’s a brief overview of the major methods for consuming marijuana.
Air-dried stem yields in Ontario have from 1998 and onward ranged from 2.6–14.0 tonnes of dry, retted stalks per hectare (1–5.5 t/ac) at 12% moisture. Yields in Kent County, have averaged 8.75 t/ha (3.5 t/ac). Northern Ontario crops averaged 6.1 t/ha (2.5 t/ac) in 1998. Statistic for the European Union for 2008 to 2010 say that the average yield of hemp straw has varied between 6.3 and 7.3 ton per ha. Only a part of that is bast fiber. Around one tonne of bast fiber and 2–3 tonnes of core material can be decorticated from 3–4 tonnes of good-quality, dry-retted straw. For an annual yield of this level is it in Ontario recommended to add nitrogen (N):70–110 kg/ha, phosphate (P2O5): up to 80 kg/ha and potash (K2O): 40–90 kg/ha. The average yield of dry hemp stalks in Europe was 6 ton/ha (2.4 ton/ac) in 2001 and 2002.
I use this for my anxiety and for my arthritis. The topical works great for my chronic neck pain. The best way to go is to get your own raw, tested material and use it in whatever form you like. It’s quite easy to make your own extract. This has worked better for me, rather than relying on a purchased, untested product – where some seem to work and others are a waste. But even with those that work, of course the cost is ridiculous and not affordable, thanks to all these corporate-pleasing laws in place, not there for the people – don’t delude yourselves.
Until very recently, the most convincing evidence that cannabis use precipitates schizophrenia came from a 15-year prospective study of cannabis use and schizophrenia in 50 465 Swedish conscripts (Andreasson et al., 1987). This study investigated the relationship between self-reported cannabis use at age 18 and the risk of being diagnosed with schizophrenia in the Swedish psychiatric case register during the next 15 years. Andreasson and colleagues found a dose–response relationship between the risk of schizophrenia and the number of times cannabis had been used by age 18 (1.3 times higher for those who had used cannabis 1–10 times, 3 times higher for those who had used cannabis 1–50 times, and 6 times higher for those who had used cannabis more than 50 times). These risks were reduced after statistical adjustment for potentially confounding variables (a psychiatric diagnosis at age 18, and parental divorce), but the relationships remained statistically significant.
Cannabis has long had an image problem, because of the extremely widespread use of “narcotic” cultivars as illegal intoxicants. The US Drug Enforcement Administration has the mandate of eliminating illicit and wild marijuana, which it does very well (Fig. 54–56). Those interested in establishing and developing legitimate industries based on fiber and oilseed applications have had to struggle against considerable opposition from many in the political and law enforcement arenas. The United States National Institute on Drug Abuse (NIDA) information web site on marijuana, which reflects a negative view of cannabis, is at www.nida.nih.gov/DrugPages/Marijuana.html, and reflects several basic fears: (1) growing Cannabis plants makes law enforcement more difficult, because of the need to ensure that all plants cultivated are legitimate; (2) utilization of legitimate Cannabis products makes it much more difficult to maintain the image of the illegitimate products as dangerous; (3) many in the movements backing development of hemp are doing so as a subterfuge to promote legalization of recreational use of marijuana; and (4) THC (and perhaps other constituents) in Cannabis are so harmful that their presence in any amount in any material (food, medicine or even fiber product) represents a health hazard that is best dealt with by a total proscription.
In the mid 1990s, the EU provided subsidization for hemp cultivation of ca. $1,050/ha. This support was instrumental in developing a hemp industry in western Europe. However, no comparable support is available in North America, and indeed those contemplating entering into hemp cultivation are faced with extraordinary costs and/or requirements in connection with licensing, security, THC analysis, and record keeping. Those involved in value-added processing and distribution are also faced with legal uncertainties and the regular threat of idiosyncratic, indeed irrational actions of various governments. Simply displaying a C. sativa leaf on advertising has led to the threat of criminal charges in the last decade in several G8 countries. Attempting to export or import hemp products among countries is presently a most uncertain activity.
In 1924, Russian botanist D.E. Janichevsky concluded that ruderal Cannabis in central Russia is either a variety of C. sativa or a separate species, and proposed C. sativa L. var. ruderalis Janisch, and Cannabis ruderalis Janisch, as alternative names. In 1929, renowned plant explorer Nikolai Vavilov assigned wild or feral populations of Cannabis in Afghanistan to C. indica Lam. var. kafiristanica Vav., and ruderal populations in Europe to C. sativa L. var. spontanea Vav. In 1940, Russian botanists Serebriakova and Sizov proposed a complex classification in which they also recognized C. sativa and C. indica as separate species. Within C. sativa they recognized two subspecies: C. sativa L. subsp. culta Serebr. (consisting of cultivated plants), and C. sativa L. subsp. spontanea (Vav.) Serebr. (consisting of wild or feral plants). Serebriakova and Sizov split the two C. sativa subspecies into 13 varieties, including four distinct groups within subspecies culta. However, they did not divide C. indica into subspecies or varieties.
"In 1937, Congress passed the first federal law to discourage cannabis production for marijuana while still permitting industrial uses of the crop (the Marihuana Tax Act; 50 Stat. 551). Under this statute, the government actively encouraged farmers to grow hemp for fiber and oil during World War II. After the war, competition from synthetic fibers, the Marihuana Tax Act, and increasing public anti-drug sentiment resulted in fewer and fewer acres of hemp being planted, and none at all after 1958.
I always tell beginners for CBD use to use full-spectrum. The full-spectrum oils contain a lot of terpenes and other good stuff along with CBD and help much more when you suffer from anxiety attacks. CBDistillery also has a wide range of potencies to choose from. Unlike, FabCBD, which offers only limited capacities, CBDistillery’s oils go up to 5000mg per bottle and it is indeed one of the best CBD oils for pain in the market
France is Europe's biggest producer (and the world's second largest producer) with 8,000 hectares (20,000 acres) cultivated. 70–80% of the hemp fibre produced in 2003 was used for specialty pulp for cigarette papers and technical applications. About 15% was used in the automotive sector, and 5-6% was used for insulation mats. About 95% of hurds were used as animal bedding, while almost 5% was used in the building sector. In 2010/2011, a total of 11,000 hectares (27,000 acres) was cultivated with hemp in the EU, a decline compared with previous year.
Although hemp and marijuana are both varieties of cannabis, there is a difference between them. The differences between these cannabis varieties are primarily evident in the way each plant is used. These differences are also documented in the language, laws, and regulations that apply to each variety. In this introduction to hemp, we’ll break down the anatomy, history, use, and legality of the hemp plant to get to the heart of not only what distinguishes it from marijuana, but also what makes it such a viable, versatile commodity.
Drug policy is always clearest at the fringes. Illegal opioids are at one end. They are dangerous. Manufacturers and distributors belong in prison, and users belong in drug-treatment programs. The cannabis industry would have us believe that its product, like coffee, belongs at the other end of the continuum. “Flow Kana partners with independent multi-generational farmers who cultivate under full sun, sustainably, and in small batches,” the promotional literature for one California cannabis brand reads. “Using only organic methods, these stewards of the land have spent their lives balancing a unique and harmonious relationship between the farm, the genetics and the terroir.” But cannabis is not coffee. It’s somewhere in the middle. The experience of most users is relatively benign and predictable; the experience of a few, at the margins, is not. Products or behaviors that have that kind of muddled risk profile are confusing, because it is very difficult for those in the benign middle to appreciate the experiences of those at the statistical tails. Low-frequency risks also take longer and are far harder to quantify, and the lesson of “Tell Your Children” and the National Academy report is that we aren’t yet in a position to do so. For the moment, cannabis probably belongs in the category of substances that society permits but simultaneously discourages. Cigarettes are heavily taxed, and smoking is prohibited in most workplaces and public spaces. Alcohol can’t be sold without a license and is kept out of the hands of children. Prescription drugs have rules about dosages, labels that describe their risks, and policies that govern their availability. The advice that seasoned potheads sometimes give new users—“start low and go slow”—is probably good advice for society as a whole, at least until we better understand what we are dealing with.
The endocannabinoid system is tonically active in control of pain, as demonstrated by the ability of SR141716A (rimonabant), a CB1 antagonist, to produce hyperalgesia upon administration to mice (Richardson et al 1997). As mentioned above, the ECS is active throughout the neuraxis, including integrative functions in the periacqueductal gray (Walker et al 1999a; Walker et al 1999b), and in the ventroposterolateral nucleus of the thalamus, in which cannabinoids proved to be 10-fold more potent than morphine in wide dynamic range neurons mediating pain (Martin et al 1996). The ECS also mediates central stress-induced analgesia (Hohmann et al 2005), and is active in nociceptive spinal areas (Hohmann et al 1995; Richardson et al 1998a) including mechanisms of wind-up (Strangman and Walker 1999) and N-methyl-D-aspartate (NMDA) receptors (Richardson et al 1998b). It was recently demonstrated that cannabinoid agonists suppress the maintenance of vincristine-induced allodynia through activation of CB1 and CB2 receptors in the spinal cord (Rahn et al 2007). The ECS is also active peripherally (Richardson et al 1998c) where CB1 stimulation reduces pain, inflammation and hyperalgesia. These mechanisms were also proven to include mediation of contact dermatitis via CB1 and CB2 with benefits of THC noted systemically and locally on inflammation and itch (Karsak et al 2007). Recent experiments in mice have even suggested the paramount importance of peripheral over central CB1 receptors in nociception of pain (Agarwal et al 2007)
In this report, researchers reviewed 16 previously published studies testing the use of various cannabis-based medicines in the treatment of chronic neuropathic pain and found some evidence that cannabis-based medicines may help with pain relief and reduce pain intensity, sleep difficulties, and psychological distress. Side effects included sleepiness, dizziness, mental confusion. The authors concluded that the potential harm of such medicines may outweigh their possible benefit, however, it should be noted that the studies used a variety of cannabis-based medicines (e.g. inhaled cannabis and sprays and oral tablets containing THC and/or CBD from plant sources or made synthetically), some of which are more likely to result in these side effects than products without THC.